Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Predictors of therapeutic efficacy of anamorelin in patients with gastric, pancreatic, and colorectal cancer.
Authors
Kazuhiro Shimomura
Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan;
Kazuhiro Shimomura , Takatsugu Ogata , Akimitsu Maeda , Yukiya Narita , Hiroya Taniguchi , Kenta Murotani , Masahiro Tajika , Kazuo Hara , Kei Muro , Kosaku Uchida
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Quality of Care/Quality Improvement
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 331)
DOI
10.1200/JCO.2023.41.4_suppl.331
Abstract #
331
Poster Bd #
D12
Abstract Disclosures
Similar Posters
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): Post-hoc analysis of two phase III studies.
First Author: David Christopher Currow
Poster
2016 ASCO Annual Meeting
Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): A pooled efficacy data analysis of two phase 3 studies.
First Author: David Christopher Currow
Poster
2023 ASCO Annual Meeting
15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.
First Author: Stein G Larsen
Poster
2023 ASCO Annual Meeting
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
First Author: Dale Randall Shepard